Pennsylvania mental health groups sue the state's Department of Public Welfare in an Oct. 4 civil action to allow access to Clozaril by all schizophrenic patients under Medicaid. Currently, Pennsylvania uses a lottery system for Clozaril treatment that selects from those who have failed at least two to three other therapies. On Sept. 10, a Kansas federal court judge ruled that the Kansas Medicaid agency must provide prescription coverage for a schizophrenic patient who had failed other therapies. The Kansas court also ordered the inclusion of Clozaril on the formulary list of drugs covered by the Kansas Medicaid program.
You may also be interested in...
Can a false-claims suit be filed if doctors have different opinions about whether a treatment was necessary? The Supreme Court won’t say.
No device-related close-out letters were released by the US FDA last month.
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.